Overview

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Status:
RECRUITING
Trial end date:
2027-11-05
Target enrollment:
Participant gender:
Summary
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
Phase:
PHASE2
Details
Lead Sponsor:
AstraZeneca